Exelixis Inc. Stock
Price
Target price
€38.57
€38.57
1.610%
0.61
1.610%
€40.48
23.07.25 / Tradegate
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Exelixis Inc. Stock
Exelixis Inc. gained 1.610% today.
The stock is an absolute favorite of our community with 43 Buy predictions and no Sell predictions.
As a result the target price of 40 € shows a slightly positive potential of 3.71% compared to the current price of 38.57 € for Exelixis Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 1.610% | 0.156% | 2.936% | 86.329% | 18.168% | 88.699% | 78.896% |
| Ironwood Pharmaceuticals | -0.750% | 4.762% | 10.924% | -89.524% | -84.286% | -94.246% | -92.235% |
| Novocure Ltd | -0.220% | -2.666% | -3.310% | -19.775% | -52.352% | -80.212% | -76.290% |
| Iovance Biotherapeutics Inc. | 26.900% | 75.003% | 111.879% | -57.815% | -51.108% | -70.792% | -85.905% |
Comments
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Morgan Stanley from $47.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Truist Financial Corporation from $55.00 to $56.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at HC Wainwright from $47.00 to $53.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45
2 Top Stocks to Buy With Less Than $100
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that
Why Exelixis Stock Is Skyrocketing Today
Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening.